PMC:7264098 / 18162-18789 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T286","span":{"begin":41,"end":49},"obj":"SP_7"},{"id":"T287","span":{"begin":64,"end":75},"obj":"UBERON:0001004"},{"id":"T288","span":{"begin":349,"end":353},"obj":"DG_47"},{"id":"T289","span":{"begin":494,"end":503},"obj":"UBERON:0002048"},{"id":"T82425","span":{"begin":41,"end":49},"obj":"SP_7"},{"id":"T86543","span":{"begin":64,"end":75},"obj":"UBERON:0001004"},{"id":"T2347","span":{"begin":349,"end":353},"obj":"DG_47"},{"id":"T12392","span":{"begin":494,"end":503},"obj":"UBERON:0002048"}],"text":"Whilst a number of MSC-related trials in COVID-19 patients with respiratory complications are underway, limited reports are available that these treatments have the potential to improve recovery and survival of these patients. Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"400","span":{"begin":50,"end":58},"obj":"Species"},{"id":"401","span":{"begin":217,"end":225},"obj":"Species"},{"id":"402","span":{"begin":310,"end":318},"obj":"Species"},{"id":"403","span":{"begin":377,"end":385},"obj":"Species"},{"id":"404","span":{"begin":450,"end":458},"obj":"Species"},{"id":"405","span":{"begin":41,"end":49},"obj":"Disease"},{"id":"406","span":{"begin":64,"end":89},"obj":"Disease"},{"id":"407","span":{"begin":562,"end":574},"obj":"Disease"}],"attributes":[{"id":"A400","pred":"tao:has_database_id","subj":"400","obj":"Tax:9606"},{"id":"A401","pred":"tao:has_database_id","subj":"401","obj":"Tax:9606"},{"id":"A402","pred":"tao:has_database_id","subj":"402","obj":"Tax:9606"},{"id":"A403","pred":"tao:has_database_id","subj":"403","obj":"Tax:9606"},{"id":"A404","pred":"tao:has_database_id","subj":"404","obj":"Tax:9606"},{"id":"A405","pred":"tao:has_database_id","subj":"405","obj":"MESH:C000657245"},{"id":"A406","pred":"tao:has_database_id","subj":"406","obj":"MESH:D012131"},{"id":"A407","pred":"tao:has_database_id","subj":"407","obj":"MESH:D007249"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Whilst a number of MSC-related trials in COVID-19 patients with respiratory complications are underway, limited reports are available that these treatments have the potential to improve recovery and survival of these patients. Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T131","span":{"begin":41,"end":49},"obj":"Disease"},{"id":"T132","span":{"begin":562,"end":574},"obj":"Disease"}],"attributes":[{"id":"A131","pred":"mondo_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A132","pred":"mondo_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"Whilst a number of MSC-related trials in COVID-19 patients with respiratory complications are underway, limited reports are available that these treatments have the potential to improve recovery and survival of these patients. Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T198","span":{"begin":7,"end":8},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T199","span":{"begin":277,"end":278},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T200","span":{"begin":443,"end":449},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"}],"text":"Whilst a number of MSC-related trials in COVID-19 patients with respiratory complications are underway, limited reports are available that these treatments have the potential to improve recovery and survival of these patients. Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T58","span":{"begin":412,"end":417},"obj":"Chemical"},{"id":"T59","span":{"begin":610,"end":615},"obj":"Chemical"}],"attributes":[{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Whilst a number of MSC-related trials in COVID-19 patients with respiratory complications are underway, limited reports are available that these treatments have the potential to improve recovery and survival of these patients. Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T23","span":{"begin":562,"end":574},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Whilst a number of MSC-related trials in COVID-19 patients with respiratory complications are underway, limited reports are available that these treatments have the potential to improve recovery and survival of these patients. Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T110","span":{"begin":0,"end":226},"obj":"Sentence"},{"id":"T111","span":{"begin":227,"end":627},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Whilst a number of MSC-related trials in COVID-19 patients with respiratory complications are underway, limited reports are available that these treatments have the potential to improve recovery and survival of these patients. Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2)."}